SAVE THE DATE: Barclays: EU MedTech & Life Sciences Investor Trip 2026

研报英文原文证据摘录

SAVE THE DATE: Barclays: EU MedTech & Life Sciences Investor Trip 2026

- Oxford Nanopore - CEO & CFO meeting

- Roche Diagnostics - CEO meeting (virtual)

- Smith & Nephew - Confirmed

- BioMerieux - TBC

Logistics information to follow once allocation process has been confirmed.

Hassan Al-Wakeel, CFA, is a Managing Director and Head of

European Medical Technology & Services Equity Research

at Barclays. He ranked #1 in his sector in the 2025 and

2024 Institutional Investor / Extel survey. Hassan joined

Barclays in 2017; he has over a decade of experience in

equity research, previously working as a Global MedTech

analyst at GLG Partners and starting his career at Deutsche

Bank. He is a CFA Charterholder and graduated with a First

Class Master's degree in Engineering Science from Oxford

University with a focus on Biomedical Engineering.

View Analyst Page

Charles Pitman-King joined Barclays in 2022 as a VP in the

European pharmaceutical team to cover a selection of

mid-cap companies. His previous experience includes

covering both mid-cap European and large-cap US

pharmaceutical companies since 2018, as well as broad

sector themes, such as the rapidly evolving COVID-19

pandemic and sector ESG themes. Prior to this, he has also

had experience covering the Aerospace and Defence

sector, and working in financial modelling. He holds a first

class Masters in Mathematics from Durham University and

has been a CFA Charterholder since 2019.

Jon Unwin is a Vice President and research analyst

covering the European Medical Technologies & Services

sector. He joined Barclays in 2025, having previously

worked at Bernstein covering Medtech and before that

covering Capital Goods and Oil Services. He is currently

studying for an MSc in Health Economics, Policy and